Serum chloride and the response to acetazolamide in patients with acute heart failure and volume overload: a post-hoc analysis from the ADVOR trial

Back

HFA Premium Access

Serum chloride and the response to acetazolamide in patients with acute heart failure and volume overload: a post-hoc analysis from the ADVOR trial

Session: Acute, advanced and worsening heart failure: prognostic aspects

Topic: Pharmacotherapy

Speaker: Doctor J. Van den Eynde (Leuven, BE)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor Jef Van den Eynde

University Hospitals (UZ) Leuven, Leuven (Belgium)

0 follower

6 more presentations in this session

Length of hospital stay, re-hospitalization rates and comorbidities in patients with worsening heart failure. Data from 3 large cohort studies in the US, Germany and Japan.

Speaker: Doctor A. Michel (Basel, CH)

Impact of defibrillators on mortality in patients with quadruple guideline-directed medical therapy: a propensity score-matched study

Speaker: Assistant Professor A. Sahin (Sivas, TR)

ICCU-HF score for predicting 1-year heart failure outcomes in patients hospitalised in intensive cardiac care units

Speaker: Doctor A. Tinggaard (Aarhus, DK)

Frailty according to the 2019 HFA-ESC definition in patients at risk for advanced heart failure: insights from the HELP-HF registry

Speaker: Doctor A. Villaschi (Rozzano, IT)

Prevention of heart failure readmission in patients with left ventricular assist device (LVAD): role of pump optimization and medical therapy

Speaker: Doctor C. Marcelli (Bologna, IT)

Access the full session

Acute, advanced and worsening heart failure: prognostic aspects

Speakers: Doctor J. Van den Eynde, Doctor A. Michel, Assistant Professor A. Sahin, Doctor A. Tinggaard, Doctor A. Villaschi...

Access

Video

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources